Carfilzomib

Carfilzomib is a second-generation, irreversible, peptide epoxyketone class proteasome inhibitor that targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50 = 5.2 nM) and the beta5i subunit of the immunoproteasome 20Si (LMP7, IC50 = 14 nM) with minimal cross reactivity to other proteases. It can induce cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, lymphoma, and various solid tumors (IC50s = 2.4-20 nM).Formal Name: (alphaS)-alpha-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide. CAS Number: 868540-17-4. Synonyms: PR-171. Molecular Formula: C40H57N5O7. Formula Weight: 719.9. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 15 mg/ml, DMSO: 15 mg/ml, Ethanol: 1 mg/ml. SMILES: O=C([C@]1(C)OC1)[C@H](CC(C)C)NC([C@@H](NC([C@@H](NC([C@H](CCC2=CC=CC=C2)NC(CN3CCOCC3)=O)=O)CC(C)C)=O)CC4=CC=CC=C4)=O. InChi Code: InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/. InChi Key: BLMPQMFVWMYDKT-NZTKNTHTSA-N.